1 study found for:    21307649 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
Conditions: Cervical Cancer;   Genital Warts
Intervention: Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years

Indicates status has not been verified in more than two years